Hepatic effects of rosiglitazone in rats with the metabolic syndrome

Basic and Clinical Pharmacology and Toxicology

Volumn 107, Issue 2, 2010, Pages 663-668

  Ackerman, Zvi ^a   Oron Herman, Mor ^b   Pappo, Orit ^a   Peleg, Edna ^b   Safadi, Rifaat ^a   Schmilovitz Weiss, Hemda ^c   Grozovski, Maria ^d  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c HASHARON HOSPITAL   (Israel)

^d ORT BRAUDE COLLEGE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALPHA TOCOPHEROL; ARYLDIALKYLPHOSPHATASE; FRUCTOSE; GLUTATHIONE REDUCTASE; MALONALDEHYDE; PHOSPHOLIPID; ROSIGLITAZONE; TRIACYLGLYCEROL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; LIPID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; ENZYME ACTIVITY; FATTY LIVER; LIPID PEROXIDATION; LIVER HISTOLOGY; MALE; METABOLIC SYNDROME X; NONHUMAN; PRIORITY JOURNAL; RAT; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; ANIMAL FOOD; CHEMICALLY INDUCED; DRUG EFFECTS; LIPID METABOLISM; LIVER; LIVER CIRRHOSIS; METABOLISM; SPRAGUE DAWLEY RAT;

RATTUS;

ADIPONECTIN; ALPHA-TOCOPHEROL; ANIMAL FEED; ANIMALS; ARYLDIALKYLPHOSPHATASE; BLOOD PRESSURE; FATTY LIVER; FRUCTOSE; GLUTATHIONE REDUCTASE; HYPOGLYCEMIC AGENTS; LIPID METABOLISM; LIPIDS; LIVER; LIVER CIRRHOSIS; MALE; MALONDIALDEHYDE; METABOLIC SYNDROME X; PHOSPHOLIPIDS; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLIDINEDIONES;

EID: 77954710226     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2010.00553.x     Document Type: Article

References (46)

1. Sanyal AJ. AGA technical review on non-alcoholic fatty liver disease. Gastroenterology 2002 123 : 1705 1725.
2. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 2009 49 : 306 317.
3. Reaven GM. Insulin resistance, hyperinsulinemia and hypertriglyceridemia in the etiology and clinical causes of hypertension. Am J Med 1991 90 : S7 12.
4. Fan JG, Li F, Cai XB, Peng YD, Ao QH, Gao Y. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J Gastroenterol Hepatol 2007 22 : 1086 1091.
5. Stein LL, Dong MH, Loomba R. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: current status. Adv Ther 2009 26 : 893 907.
6. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001 96 : 519 525.
7. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003 38 : 1008 1017.
8. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004 39 : 188 196.
9. Tiikkainen M, Hakkinen AM, Korsheninnikova E, Nyman T, Makimattila S, Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004 53 : 2169 2176.
10. Sanyal AJ, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling RK et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004 2 : 1107 1115.
11. Lutchman G, Modi A, Kleiner DE, Promrat K, Heller T, Ghany M et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 2007 46 : 424 429.
12. Tahan V, Eren F, Avsar E, Yavuz D, Yuksel M, Emekli E et al. Rosiglitazone Attenuates liver inflammation in a rat model of nonalcoholic steatohepatitis. Dig Dis Sci 2007 52 : 3465 3472.
13. Ota T, Takamura T, Kurita S, Matsuzawa N, Kita Y, Uno M et al. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterology 2007 132 : 282 293.
14. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006 355 : 2297 2307.
15. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008 135 : 1176 1184.
16. Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial. Gastroenterology 2008 135 : 100 110.
17. Ratziu V, Charlotte F, Bernhardt C, Giral P, Halbron M, Lenaour G et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 2010 51 : 445 453.
18. Nan YM, Fu N, Wu WJ, Liang BL, Wang RQ, Zhao SX et al. Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice. Scand J Gastroenterol 2009 44 : 358 365.
19. Bedoucha M, Atzpodien E, Boelsterli UA. Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones. J Hepatol 2001 35 : 17 23.
20. Leiter EH, Reifsnyder PC, Zhang W, Pan HJ, Xiao Q, Mistry J. Differential endocrine responses to rosiglitazone therapy in new mouse models of type 2 diabetes. Endocrinology 2006 147 : 919 926.
21. Garcia-Ruiz I, Rodriguez-Juan C, Diaz-Sanjuan T, Martinez MA, Munoz-Yague T, Solis-Herruzo JA. Effects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice. Hepatology 2007 46 : 414 423.
22. Caldwell SH, Argo CK. Divergent effects of peroxisome proliferator-activated receptor-gamma ligands in human and mouse nonalcoholic steatohepatitis. Hepatology 2007 46 : 285 287.
23. Ackerman Z, Oron-Herman M, Grozovski M, Rosenthal T, Pappo O, Link G et al. Fructose-induced fatty liver disease: hepatic effects of blood pressure and plasma triglyceride reduction. Hypertension 2005 45 : 1012 1018.
24. Ackerman Z, Oron-Herman M, Rosenthal T, Pappo O, Link G, Sela BA et al. Effects of amlodipine, captopril, and bezafibrate on oxidative milieu in rats with fatty liver. Dig Dis Sci 2008 53 : 777 784.
25. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity. Diabetes Care 2000 23 : 57 63.
26. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Non-alcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999 94 : 2467 2474.
27. Safadi R, Ohta M, Alvarez CE, Fiel MI, Bansal M, Mehal WZ et al. Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology 2004 127 : 870 882.
28. Barnes H, Blackstock J. Estimation of lipids in marine animals and tissues: detailed investigation of the sulphophosphovaniliun method for total lipids. J Exp Mar Biol Ecol 1973 12 : 103 118.
29. Bartlett GR. Colorimetric assay methods for free and phosphorylated glyceric acids. J Biol Chem 1959 234 : 469 471.
30. Folch J, lees M, Sloane Stanly GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957 226 : 497 509.
31. Gottfried SP, Rosenberg B. Improved manual spectrophotometric procedure for determination of triglycerides. Clin Chem 1973 19 : 1077 1078.
32. Taylor RP, Broccoli AV, Grisham CM. Enzymatic and colorimetric determination of total serum cholesterol. An undergraduate biochemistry laboratory experiment. J Chem Educ 1978 55 : 36 64.
33. Yagi K. Lipid peroxides and human diseases. Chem Phys Lipids 1987 45 : 337 351.
34. Baker H, Frank O, DeAngelis B, Feingold S. Plasma tocopherol in man at various times after ingesting free and acetylated tocopherol. Nutr Rep Int 1980 21 : 531 536.
35. Gan KN, Smolen A, Eckerson HW, La Du BN. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 1991 19 : 100 106.
36. Carlberg I, Mannervik B. Glutathione reductase. Methods Enzymol 1985 113 : 484 490.
37. Bradford MM. A rapid and sensitive method for quantitation of micrograme quantities of protein utilizing the principle of protein dye-binding. Anal Biochem 1976 72 : 248 254.
38. Shan XQ, Aw TY, Jones DP. Glutathione-dependent protection against oxidative injury. Pharmacol Ther 1990 47 : 61 71.
39. Chaudhry J, Ghosh NN, Roy K, Chandra R. Antihyperglycemic effect of a new thiazolidinedione analogue and its role in ameliorating oxidative stress in alloxan-induced diabetic rats. Life Sci 2007 80 : 1135 1142.
40. Narayanan PK, Hart T, Elcock F, Zhang C, Hahn L, McFarland D et al. Troglitazone-induced intracellular oxidative stress in rat hepatoma cells: a flow cytometric assessment. Cytometry A 2003 52 : 28 35.
41. Chojkier M. Troglitazone and liver injury: in search of answers. Hepatology 2005 41 : 237 246.
42. Inoue I, Katayama S, Takahashi K, Negishi K, Miyazaki T, Sonoda M et al. Troglitazone has a scavenging effect on reactive oxygen species. Biochem Biophys Res Commun 1997 235 : 113 116.
43. Akyüz F, Demir K, Ozdil S, Aksoy N, Poturǒlu S, Ibrişim D et al. The effects of rosiglitazone, metformin, and diet with exercise in nonalcoholic fatty liver disease. Dig Dis Sci 2007 52 : 2359 2367.
44. Whitehead JP, Richards AA, Hickman IJ, Macdonald GA, Prins JB. Adiponectin - a key adipokine in the metabolic syndrome. Diabetes Obes Metab 2006 8 : 264 280.
45. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003 112 : 91 100.
46. Chao L, Marcus-Samuels B, Mason MM, Moitra J, Vinson C, Arioglu E et al. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J Clin Invest 2000 106 : 1221 1228.